Therapeutic Potential of Antioxidants and Hybrid TEMPOL Derivatives in Ocular Neurodegenerative Diseases: A Glimpse into the Future

Simple item page
dc.creatorAmankwa, Charles E.
dc.creatorKodati, Bindu
dc.creatorDonkor, Nina
dc.creatorAcharya, Suchismita
dc.creator.orcid0000-0001-5098-5555 (Acharya, Suchismita)
dc.date.accessioned2023-12-01T20:27:50Z
dc.date.available2023-12-01T20:27:50Z
dc.date.issued2023-11-25
dc.description.abstractReactive oxygen species play a significant role in the pathogenesis of various ocular neurodegenerative diseases especially glaucoma, age-related macular degeneration (AMD), and ocular ischemic stroke. Increased oxidative stress and the accumulation of ROS have been implicated in the progression of these diseases. As a result, there has been growing interest in exploring potential therapeutic and prophylactic strategies involving exogenous antioxidants. In recent years, there have been significant advancements in the development of synthetic therapeutic antioxidants for targeting reactive oxygen species (ROS) in neurodegenerative diseases. One area of focus has been the development of hybrid TEMPOL derivatives. In the context of ocular diseases, the application of next-generation hybrid TEMPOL antioxidants may offer new avenues for neuroprotection. By targeting ROS and reducing oxidative stress in the retina and optic nerve, these compounds have the potential to preserve retinal ganglion cells and trabecular meshwork and protect against optic nerve damage, mitigating irreversible blindness associated with these diseases. This review seeks to highlight the potential impact of hybrid TEMPOL antioxidants and their derivatives on ocular neurodegenerative disorders.
dc.description.sponsorshipThis research was funded by the National Institute of Health, grant number R01EY029823 awarded to S.A.
dc.identifier.citationAmankwa, C. E., Kodati, B., Donkor, N., & Acharya, S. (2023). Therapeutic Potential of Antioxidants and Hybrid TEMPOL Derivatives in Ocular Neurodegenerative Diseases: A Glimpse into the Future. Biomedicines, 11(11), 2959. https://doi.org/10.3390/biomedicines11112959
dc.identifier.issn2227-9059
dc.identifier.issue11
dc.identifier.urihttps://hdl.handle.net/20.500.12503/32441
dc.identifier.volume11
dc.publisherMDPI
dc.relation.urihttps://doi.org/10.3390/biomedicines11112959
dc.rights.holder© 2023 by the authors.
dc.rights.licenseAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceBiomedicines
dc.subjectSA-10
dc.subjectSA-2
dc.subjectSA-9
dc.subjectTEMPOL derivatives
dc.subjectglaucoma
dc.subjecthybrid small molecules
dc.subjectneuroprotection
dc.subjectnitric oxide
dc.subjectoxidative stress
dc.subjectreactive oxygen species
dc.subjectretina ganglion cells
dc.subjecttrabecular meshwork
dc.titleTherapeutic Potential of Antioxidants and Hybrid TEMPOL Derivatives in Ocular Neurodegenerative Diseases: A Glimpse into the Future
dc.typeArticle
dc.type.materialtext

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
10.3390_biomedicines11112959.pdf
Size:
14.43 MB
Format:
Adobe Portable Document Format
Description:
full text article
Download

Collections

Publications -- Suchismita Acharya